http://www.fpnotebook.com/
NSAID Gastrointestinal Adverse Effects
Aka: NSAID Gastrointestinal Adverse Effects
- See Also
- NSAID
- NSAID Alternatives
- Risk Factors: NSAID related GI adverse effects
- Age over 60 years (decreased GI protection)
- Peptic Ulcer Disease history
- Concurrent Corticosteroid use
- Concurrent oral Anticoagulation (Coumadin, Aspirin)
- High dose NSAID
- Risk Factors: Relative Risks of GI adverse effects
- Lowest Risk: COX2 Inhibitors (Selective)
- Celecoxib (Celebrex)
- Rofecoxib (Vioxx)
- Low Risk (Non-Selective NSAIDs)
- Ibuprofen (Relative Risk 1.0 to 2.7)
- Fenoprofen or Nalfon (Relative Risk 1.6)
- Aspirin (Relative Risk 1.6)
- Diclofenac or Voltaren (Relative Risk 1.8 to 4.0)
- Sulindac or Clinoril (Relative Risk 2.1)
- Nabumetone or Relafen
- Etodolac or Lodine
- Salsalate
- Medium Risk
- Diflunisal or Dolobid (Relative Risk 2.2)
- Naproxen or Naprosyn (Relative Risk 2.2 to 5.2)
- Indomethacin or Indocin (Relative Risk 2.4 to 5.3)
- Tolmetin or Tolectin (Relative Risk 3.0)
- Meloxicam or Mobic (Relative Risk 4.0)
- High Risk
- Piroxicam or Feldene (Relative Risk 3.8 to 9.3)
- Ketoprofen or Orudis (Relative Risk 4.2 to 5.7)
- Azapropazone (Relative Risk 9.2)
- Flurbiprofen or Ansaid
- Ketorolac or Toradol (Relative Risk 14.0)
- Adverse Effects: Gastroduodenal Ulcer Incidence by endoscopy (12 weeks)
- Naprosyn: 35%
- Ibuprofen: 23-29% (2 different trials)
- Diclofenac: 10%
- Rofecoxib: 5-8% (25-50 mg)
- Celecoxib: 7%
- Placebo: 4-7% (2 different trials)
- References
- (1999) Med Lett Drugs Ther 41(1045): 11-14
- Laine (1999) Gastroenterology 116:A229
- Management: Prophylaxis
- General
- Always use NSAID with food or milk
- COX2 Inhibitors have no advantage over standard NSAID
- Consider screening for Helicobacter Pylori before use
- Indications for prophylaxis (avoid NSAIDs if possible)
- Age over 75 years
- Concurrent Warfarin therapy
- History of Peptic Ulcer Disease
- History of Gastrointestinal Bleeding
- History of Coronary Artery Disease
- Misoprostol (Cytotec)
- Dose: 100-200 ug tid to qid
- Replaces prostaglandins at Stomach lining
- Allows use of NSAIDS in Peptic Ulcer Disease
- Causes significant dose limiting Diarrhea
- Sucralfate
- Ineffective at preventing NSAID related Peptic Ulcers
- H2 Receptor Antagonists (e.g. Zantac, Tagamet)
- Not recommended (may mask GI symptoms)
- Prevents Duodenal Ulcer, not Gastric Ulcer
- Consider high dose H2 Antagonist
- Omeprazole
- Heals, but may not protect from formation
- References
- Henry (1996) BMJ 312:1563-6
- (1999) Med Lett Drugs Ther 41(1045): 11-14
- Masso (2010) Arthritis Rheum 62(6): 1592-1601